华熙生物
(688363)
| 流通市值：272.44亿 | | | 总市值：272.44亿 |
| 流通股本：4.82亿 | | | 总股本：4.82亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,260,691,517.33 | 1,077,926,981.07 | 5,370,770,254.64 | 3,874,744,443.18 |
| 营业收入 | 2,260,691,517.33 | 1,077,926,981.07 | 5,370,770,254.64 | 3,874,744,443.18 |
| 二、营业总成本 | 1,981,640,358.55 | 944,321,696.14 | 5,039,860,099.8 | 3,419,165,826.77 |
| 营业成本 | 655,733,454.52 | 300,184,272.82 | 1,392,561,666.02 | 1,010,187,630.31 |
| 税金及附加 | 27,156,541.16 | 14,603,538.19 | 65,522,692.57 | 49,073,723.5 |
| 销售费用 | 807,998,012.65 | 394,120,362.62 | 2,464,088,147.25 | 1,630,984,967.48 |
| 管理费用 | 275,140,183.32 | 135,015,254.12 | 658,393,252.12 | 422,950,678.62 |
| 研发费用 | 231,101,906.21 | 104,972,584.01 | 466,249,796.43 | 313,104,634.64 |
| 财务费用 | -15,489,739.31 | -4,574,315.62 | -6,955,454.59 | -7,135,807.78 |
| 其中:利息费用 | 1,972,694.3 | 1,894,495.26 | 2,196,058.28 | 1,647,871.59 |
| 其中:利息收入 | 3,757,593.96 | 1,607,894.88 | 14,111,268.33 | 12,241,765 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 556,788.66 | -3,412.62 | 1,415,364 | 32,136.99 |
| 加:投资收益 | -5,773,140.64 | -3,610,618.41 | -12,536,457.12 | -4,995,868.91 |
| 资产处置收益 | -445,465.9 | - | -118,904.82 | -7,940.78 |
| 资产减值损失(新) | -41,390,475.33 | 983,639.43 | -159,086,390.37 | -18,153,627.1 |
| 信用减值损失(新) | -27,667,481.57 | -21,668,865.3 | -29,809,781.83 | -39,832,453 |
| 其他收益 | 56,704,687.59 | 24,523,697.21 | 85,165,723.59 | 43,503,891.72 |
| 四、营业利润 | 261,036,071.59 | 133,829,725.24 | 215,939,708.29 | 436,124,755.33 |
| 加:营业外收入 | 1,467,792.29 | 285,111.82 | 2,822,410.93 | 2,313,821.26 |
| 减:营业外支出 | 2,179,436.83 | 759,905.55 | 5,369,216.34 | 1,869,466.61 |
| 五、利润总额 | 260,324,427.05 | 133,354,931.51 | 213,392,902.88 | 436,569,109.98 |
| 减:所得税费用 | 39,520,992.58 | 32,218,761.46 | 44,986,987.51 | 77,519,223.85 |
| 六、净利润 | 220,803,434.47 | 101,136,170.05 | 168,405,915.37 | 359,049,886.13 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 220,803,434.47 | 101,136,170.05 | 168,405,915.37 | 359,049,886.13 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 220,851,905.02 | 101,893,380.76 | 174,267,399.74 | 362,023,904.69 |
| 少数股东损益 | -48,470.55 | -757,210.71 | -5,861,484.37 | -2,974,018.56 |
| 扣除非经常损益后的净利润 | 173,745,743.69 | 81,907,595.29 | 107,271,950.81 | 326,504,488.15 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.46 | 0.21 | 0.36 | 0.75 |
| (二)稀释每股收益 | 0.46 | 0.21 | 0.36 | 0.75 |
| 八、其他综合收益 | 51,143,889.08 | 14,066,443.87 | -23,891,534.78 | -1,856,452.6 |
| 归属于母公司股东的其他综合收益 | 51,143,889.08 | 14,066,443.87 | -23,891,534.78 | -1,856,452.6 |
| 九、综合收益总额 | 271,947,323.55 | 115,202,613.92 | 144,514,380.59 | 357,193,433.53 |
| 归属于母公司股东的综合收益总额 | 271,995,794.1 | 115,959,824.63 | 150,375,864.96 | 360,167,452.09 |
| 归属于少数股东的综合收益总额 | -48,470.55 | -757,210.71 | -5,861,484.37 | -2,974,018.56 |
| 公告日期 | 2025-08-27 | 2025-04-26 | 2025-04-11 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |